ALK expression favorably impacts the prognosis of NRAS-mutated metastatic melanomas

SIMONA OSELLA-ABATE¹, ELISABETTA MEREU²*, ELISA PELLEGRINO², ELISA BERGAGGIO², SIMONE RIBERO³, LUCA BERTERO², FRANCESCO LISA³, MARIA TERESA FIERRO³, MAURO GIULIO PAPOTTI⁴ and ROBERTO PIVA²

¹Department of Medical Sciences, Pathology Unit; ²Department of Molecular Biotechnology and Health Sciences, Center for Experimental Research and Medical Studies; ³Department of Medical Sciences, Dermatology Unit; ⁴Department of Oncology, Pathology Unit, University of Torino, I-10126 Torino, Italy

Received February 12, 2018; Accepted August 31, 2018

DOI: 10.3892/ol.2018.9560

Abstract. Recent studies reported the expression of anaplastic lymphoma kinase (ALK) in malignant melanomas. The aim of this study was to investigate whether ALK expression is associated with specific clinical and molecular characteristics of melanoma metastases, and to evaluate its correlation with survival outcomes. Seventy-one patients with metastatic melanoma were investigated. Clinical features and survival outcomes were analyzed and correlated to ALK expression, as detected by immunohistochemistry and reverse transcription-quantitative polymerase chain reaction, and to the mutational status of BRAF, KRAS, NRAS, and PIK3CA. No translocations or ALK alternative isoforms were identified. ALK expression was mainly detected in NRAS mutated metastatic lesions. Interestingly, among NRAS-mutated patients, ALK positive samples displayed a significantly more favorable outcome in terms of disease specific survival, as compared to ALK negative ones. In conclusion, we suggest that ALK positive/NRAS mutated metastases represent a specific subset of metastatic melanomas, associated with a better prognosis. Validation of these observations in larger cohorts could contribute to understand the molecular events cooperating to melanoma progression, in addition to open new perspectives in the clinical and therapeutic management of this subgroup of patients.

Introduction
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor frequently rearranged, mutated, or amplified in specific neoplastic diseases, including lymphoma, neuroblastoma, non-small cell lung cancer, and to a lesser extent in melanoma (1). In addition, ALK-specific mRNA and protein have been described in several cell lines from solid tumors of ectodermal origin, including melanoma (2). ALK break points have been identified in four acral cases (6.9%) of acral/mucosal melanomas from southern China (3). More recently, a novel ALK isoform derived from a de novo transcription initiation (ATI) site in ALK intron 19 (ALKATI) has been described by Wiesner et al (4). Using the RNA-seq dataset of the TCGA project, these authors found ALKATI expression in 11% of melanoma patients (38/334) and sporadically in other human cancer types, but not in normal tissues (4). Thereafter, the same group identified ALKATI expression in 3% of 303 metastatic melanoma patients (5).

In the present study, we investigated the prognostic significance of ALK expression, as detected by immunohistochemistry and reverse transcription-quantitative polymerase chain reaction (RT-qPCR), in a cohort of metastatic melanomas characterized by BRAF, KRAS, NRAS and PIK3CA mutational status.

Materials and methods

Patients. A retrospective series of 71 metastatic melanoma patients with complete clinico-pathological information underwent mutational analyses at the Pathology Unit and were followed-up at the Dermatologic Clinic of ‘Città della Salute e della Scienza’ University Hospital (Torino, Italy). The study was conducted in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans and within guidelines and regulations by the Research Ethics Committee of the University of Turin. Clinical, epidemiological and histological data were collected from the medical history of patients, all diagnosed, treated and followed-up according to previously reported protocols, after written informed consent (6-8).
Disease specific survival (DSS) was calculated from the date of primary lesion diagnosis to the date of patient death or last follow-up. Disease free interval (DFI) was calculated from the date of primary lesion diagnosis to the date of tumour progression/recurrence or last follow-up. Ethical approval for the present study was obtained from the Ethical Committee of our Institution.

**Mutational status assessment.** Metastatic tumor sections were submitted to DNA extraction as previously described (9). Mutational detection was performed using the Sequenom MassARRAY® system (Sequenom, San Diego, CA, USA) in conjunction with The Myriad Colon Status kit that identifies 58, 54, 23 and 66 nucleotide substitutions in the KRAS, NRAS, BRAF and PIK3CA genes, respectively. Mutant and wild type alleles were discriminated using the Sequenom MassARRAY® Analyser 4 platform.

**ALK immunostaining.** Melanoma metastases used for the study were previously fixed in 4% buffered formaldehyde, routinely processed and paraffin embedded. For each case, three micrometer-thick paraffin sections were collected on superfrost plus slides and tested by immunohistochemistry using anti-ALK rabbit monoclonal antibody (clone D5F3; Ventana Medical Systems, Inc., Tucson, AZ, USA). ALK detection was performed on the fully automated Ventana BenchMark XT System using the recommended protocol. ALK immunostaining was evaluated by two independent pathologists applying a 4-tier (0-3) scoring scheme (negative: 0; mild cytoplasmic: 1; moderate smooth cytoplasmic: 2; intense granular cytoplasmic staining: 3) with either diffuse or focal pattern.

**ALK transcript detection.** Total RNA from formalin-fixed paraffin embedded (FFPE) samples were extracted using the miRNAeasy FFPE Kit (QIAGEN), according to the manufacturer’s protocols. cDNA was obtained from 0.2 µg of total RNA treated previously with RNase-free DNase (Promega Corporation, Madison, WI, USA) using reverse transcriptase SuperScript III (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and gene-specific reverse primers (Table I). RT-qPCR was performed with Thermal iCycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using iQ SYBR Green Supermix (Bio-Rad Laboratories, Inc.), according to the manufacturer's instructions. The PCR cycling conditions were as follows: 95°C for 5 min, followed by 40 cycles at 94°C for 10 sec and 60°C for 30 sec. Oligonucleotide primer pairs used for RT-qPCR were designed with PrimerBLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) to obtain amplicons of 70-110 bp (Table I). To confirm amplification specificity, PCR products were subjected to the analysis of melting curve, linearity, and slope of standard curve. PCR assays were performed in triplicate. Gene-expression results were normalized to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) expressions and quantified using the ΔΔCt method, as previously described (10). Samples with GAPDH Ct value >30 were excluded from the analysis. Expression levels of ALK exons were compared to commercially available RNA from SH-SY5Y neuroblastoma cell line and detect full length ALK expression was significantly (p=<0.001) enriched in NRAS mutated metastases (9 out of 22; Table II). No statistically significant difference in DFI or DSS was observed between ALK positive and negative patients overall. However, among NRAS mutated patients (11 NRAS Q61R, 11 NRAS Q61K), ALK positive samples (5 NRAS Q61R, 4 NRAS Q61K; Tables III and IV) displayed a significantly better DSS compared to ALK negatives (P=0.050; Fig. 1D and E). In NRAS mutated patients ALK expression was not correlated with other clinico-pathological variables.

**Discussion**

Melanoma represents the fifth most common tumour in humans and is considered one of the most invasive, therapy-resistant and metastatic malignancy, with only 10% of metastatic patients surviving 5 years post-diagnosis. In addition, over the past decades, its incidence has been increasing by 3-8% per year in Western countries (16,17). Therefore, a deeper
understanding of the molecular events regulating melanoma aggressiveness and metastatic dissemination is essential to develop new relevant biomarkers and therapeutic strategies. In the present study, according to previous reports (5), we have documented that ALK protein expression can be detected by immunohistochemistry in a significant subset of

Table I. ALK gene-specific reverse primers.

| Gene       | Forward primer 5'-3' | Reverse primer 5'-3' | Use   |
|------------|----------------------|----------------------|-------|
| ALK Ex 2/3 | ALK1718F CTGTCTCATCGCAGCCGATA | ALK1790R GTGGAGGGGAATACTCC AGC | RT    |
|            |                      | ALK1798R GTCATGCAGTGAGGAGG | RT-qPCR |
| ALK Ex 20/21| ALK4284F TGCCCGGAAAACATCACC | ALK4371R TTGGGATTTCGGGACAC CTTG | RT    |
|            |                      | ALK4380R CTTGGGTGTTGGGCA TTC | RT-qPCR |
| ALK Ex 28/29| ALK5050F GCAACATCGCTGAAGACA | ALK5140R AGCGGCTTGTATTACAT CGTG | RT    |
|            |                      | ALK5144R GCAAAGCGGTGTTGATT ACA | RT-qPCR |
| HK         | GAPDH150F TCTTTTTGCRTCAGCGAGCCGAG | GAPDH150R TGACCAGGCGGCAATA CGAC | RT-qPCR |

ALK, Anaplastic lymphoma kinase; GAPDH, (glyceraldehyde-3-phosphate dehydrogenase); F, forward; R, reverse; HK, housekeeping gene.

Table II. Clinical characteristics of patients across mutational status.

| Characteristics          | Total | WT (n=19) | BRAF-mutated (n=30) | NRAS-mutated (n=22) | P-value |
|--------------------------|-------|-----------|---------------------|---------------------|---------|
| Sex                      |       |           |                     |                     |         |
| Female                   | 29    | 8         | 14                  | 7                   | 0.556   |
| Male                     | 42    | 11        | 16                  | 15                  |         |
| Age, years, median (range)| 62 (25-86) | 66 (39-83) | 53 (25-83) | 67 (32-79) | 0.002   |
| Breslow, mean ± SD       | 3.67±2.61 | 4.26±2.57 | 3.44±2.95 | 3.33±1.96 | 0.500   |
| Histotype                |       |           |                     |                     |         |
| SSM                      | 35    | 7         | 16                  | 12                  | 0.749   |
| NM                       | 12    | 4         | 4                   | 4                   |         |
| Otherα                   | 24    | 8         | 10                  | 6                   |         |
| Ulceration               |       |           |                     |                     |         |
| Absent                   | 53    | 14        | 20                  | 19                  | 0.271   |
| Present                  | 18    | 5         | 10                  | 3                   |         |
| Mitosis                  |       |           |                     |                     |         |
| <1                       | 36    | 8         | 14                  | 14                  | 0.328   |
| ≥1                       | 35    | 11        | 16                  | 8                   |         |
| Stage at diagnosis       |       |           |                     |                     |         |
| I/II                     | 37    | 11        | 18                  | 8                   | 0.206   |
| III                      | 27    | 8         | 10                  | 9                   |         |
| IV                       | 7     | 0         | 2                   | 5                   |         |
| ALK IHC                  |       |           |                     |                     |         |
| Negative                 | 61    | 19        | 29                  | 13                  | <0.001  |
| Positive                 | 10    | 0         | 1                   | 9                   |         |

*Other histotypes include lentigo maligna melanoma, acral lentiginous melanoma, amelanotic melanoma or spitzoid melanoma. WT, wild type; F, female; M, male; SSM, superficial spreading melanoma; NM, nodular melanoma; IHC, immunohistochemistry; SD, standard deviation.
Figure 1. (A) Immunostaining of a representative ALK negative melanoma metastasis (magnification, x20); (B) Immunostaining of a representative ALK positive melanoma metastasis (magnification, x20); (C) Expression of full length ALK transcript as detected by RT-qPCR; (D) DFI and (E) DSS Kaplan-Meier curves in NRAS mutated patients on the basis of ALK expression. ALK, anaplastic lymphoma kinase; DFI, disease free interval; DSS, disease specific survival.

Table III. Clinical characteristics of NRAS mutated patients.

| Characteristics          | Total | ALK IHC negative | ALK IHC positive | P-value |
|--------------------------|-------|------------------|------------------|---------|
| Sex                      |       |                  |                  | 0.899   |
| Female                   | 7     | 4                | 3                |         |
| Male                     | 15    | 9                | 6                |         |
| Age, years, median (interval) | 67 (32-79) | 68 (32-78) | 66 (46-79) | 1.000   |
| Breslow, mean ± SD       | 3.33±1.96 | 3.17±1.32 | 3.58±2.81 | 0.707   |
| Histotype                |       |                  |                  | 0.868   |
| SSM                      | 12    | 7                | 5                |         |
| NM                       | 4     | 2                | 2                |         |
| Other*                   | 6     | 4                | 2                |         |
| Ulceration               |       |                  |                  | 0.271   |
| Absent                   | 19    | 12               | 7                |         |
| Present                  | 3     | 1                | 2                |         |
| Mitosis                  |       |                  |                  | 0.378   |
| <1                       | 14    | 9                | 5                |         |
| ≥1                       | 8     | 4                | 4                |         |
| Stage at diagnosis       |       |                  |                  | 0.542   |
| II                       | 8     | 4                | 4                |         |
| III                      | 9     | 5                | 4                |         |
| IV                       | 5     | 4                | 1                |         |
| First site of progression|       |                  |                  | 0.683   |
| Regional                 | 18    | 11               | 7                |         |
| Distant                  | 4     | 2                | 2                |         |

*Other histotypes include lentigo maligna melanoma, acral lentiginous melanoma, amelanotic melanoma or spitzoid melanoma. F, female; M, male; SSM, superficial spreading melanoma; NM, nodular melanoma; IHC, immunohistochemistry; SD, standard deviation.
metastatic melanomas (10 out 71, 14%), with variable immunoreactivity scores ranging from focal/weak to diffuse/strong. Interestingly, in our series 9 out of 10 ALK positive patients were NRAS mutated. Busam and colleagues detected ALK immunoreactivity in metastatic tumors independently on the BRAF or NRAS mutational status (5).

In melanomas, NRAS activating mutations (present in 15-20% of cases) have been associated with aggressive clinical behaviour, and lack of effective treatment options, as well as with poor outcome and lower median overall survival (18,19). In particular, the presence of NRAS mutations correlates to shorter survival in stage IV melanomas and it is associated with a higher risk of central nervous system involvement (19). In our study we observed that, among NRAS-mutated patients, those ALK positive showed a more favourable outcome in term of DSS, when compared to ALK negative ones. Even though the statistical significance of this observation needs to be confirmed in a larger cohort of patients, its interpretation could open new scenarios. The observation that ALK expression in metastatic melanomas plays a physiological or pathological function still remains an open issue. In our series no ALK translocations or alternative isoforms were detected. This observation suggests that ALK expression is most likely related to the neuroectodermal origin of melanoma cells (20). Indeed, it has been shown that ALK protein is variably expressed in the cytoplasm and/or nucleus of developing central and peripheral nervous system during embryogenesis, and its expression is maintained in the adult at lower level in several tissues, including keratinocytes and melanocytes (http://www.proteinatlas.org/ENSG00000171094-ALK/tissue/skin) (2,13,21,22). The correlation between ALK expression and NRAS mutation could be ascribed to the fact that NRAS mutations occur at the stage of neural crest and are an early somatic event in the development of the majority of melanomas (22,23). The central nervous system (CNS) is a frequent site of disease progression in melanoma patients, with palliative radiotherapy usually being administered to the CNS metastasis. Recently, a combination of RT and systemic immunotherapy has been proposed for the treatment of stage IV melanoma (24). ALK positive patients could represent a novel subgroup to treat with multimodal therapy comprehensive of TKI, as described in NSCLC brain metastases (25). However, additional clinical studies are needed to determine the efficacy of targeted therapies in melanomas expressing ALK (26).

A larger study is desirable to better clarify, confirm, or possibly rule out the effective ALK reliability as a possible indicator of less aggressive pattern in NRAS-mutated metastatic melanoma patients. If confirmed, ALK positive/NRAS mutated metastatic melanomas could represent a novel clinical entity and a new therapeutic challenge in metastatic melanoma patients.

Acknowledgements

The authors would like to acknowledge technical support in immunohistochemical procedures to Dr Maria Stella Scalzo, Dr Francesca Veneziano and Dr Chiara Musuraca (Department of Medical Sciences, Pathology Unit, University of Torino).

Funding

This research received funding specifically appointed to the Department of Medical Sciences from the Italian Ministry for Education, University and Research under the programme ‘Dipartimenti di Eccellenza 2018-2022’ and has been supported by grants from Ministero dell’Istruzione, dell’Università e della Ricerca (grant no. Ex60% 2015; received by SOA), Lanzavecchia-Lastretti Foundation for ‘Progetto Melanoma’, Associazione Italiana per la Ricerca sul Cancro (grant no. IG-13358), Compagnia di San Paolo (grant no. TO_Call2_2012_0061) and Fondazione CRT (grant no. 2014_1105; received by RP).

Availability of data and materials

The data that support the findings of the present study are available from Città della Salute e della Scienza Hospital of
Torino, Department of Medical Sciences University of Torino, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Città della Salute e della Scienza Hospital of Torino and Department of Medical Sciences University of Torino.

Authors’ contributions

RP, EM and SOA designed and supervised the study, obtained funding and wrote the manuscript approved by all authors. EP and EB performed the RT-PCR experiments. FL contributed substantially to the design and execution of immunohistochemistry experiments, and preparation of the manuscript. LB and MP provided samples, and designed and supervised the pathological evaluation of samples. SR and MTF supervised the clinical data management and contributed to the statistical analysis.

Ethics approval and consent to participate

The present study was performed in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans and within guidelines and regulations by the Research Ethics Committee of the University of Turin. The present study was approved by the Research Ethics Committee of the University of Turin.

Patient consent for publication

Written informed consent was obtained from all patients.

Competing interests

The authors declare that they have no competing interests.

References

1. Chiarle R, Voena C, Ambrogio C, Piva R and Inghirami G: The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8: 11-23, 2008.
2. Dirks WG, Fährlich S, Lis Y, Becker E, MacLeod RA and Drexler HG: Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int J Cancer 100: 49-56, 2002.
3. Niu HT, Zhou QM, Wang F, Shao Q, Guan YY, Wen XZ, Chen LZ, Feng QS, Li W, Zeng YX and Zhang XS: Identification of anaplastic lymphoma kinase breakpoint points and oncogenic mutation profiles in acral/mucosal melanomas. Pigment Cell Melanoma Res 26: 646-653, 2013.
4. Wiesner T, Lee W, Obenauf AC, Ran L, Murali R, Zhang QF, Wong EW, Hu W, Scott SN, Shah RH et al: Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature 526: 453-457, 2015.
5. Busam KJ, Vilain RE, Lum T, Busam JA, Hollmann TJ, Saw RP, Coit DC, Scolyer RA and Wiesner T: Primary and metastatic cutaneous melanomas express ALK through alternative transcriptional initiation. Ann J Surg Pathol 40: 786-795, 2016.
6. Sanlorenzo M, Ribero S, Osella-Abate S, Zuniga D, Marenco F, Macriop G, Fierro MT, Bernengo MG and Quaglino P: Prognostic differences across sexes in melanoma patients: What has changed from the past? Melanoma Res 24: 568-576, 2014.
7. Ribero S, Osella-Abate S, Sanlorenzo M, Balagna E, Senetta R, Fierro MT, Macriop G, Macari L, Sapino A and Quaglino P: Sentinel lymph node biopsy in thick-melanoma patients (N=350): What is its prognostic role? Ann Surg Oncol 22: 1967-1973, 2015.
8. Osella-Abate S, Ribero S, Sanlorenzo M, Maule MM, Richardi L, Merletti F, Tomasicini M, Marra E, Macriop G, Fierro MT and Quaglino P: Risk factors related to late metastases in 1,372 melanoma patients disease free more than 10 years. Int J Cancer 136: 2453-2457, 2015.
9. Mariani S, Di Bello C, Bonello L, Tondat F, Pacchioni D, Molinaro L, Barreca A, Macri L, Chiussa L, di Celle PF et al: Flexible lab-tailored cut-offs for suitability of formalin-fixed tumor samples for diagnostic mutational analyses. PLoS One 10: e0121815, 2015.
10. Agnelli L, Mereu E, Pellegrino E, Limongi T, Kwee I, Bergaglio E, Ponzioni M, Zamo A, Iqbal J, Piccaluga PP et al: Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood 120: 1274-1284, 2012.
11. Scarfo I, Pellegrino E, Mereu E, Kwee I, Agnelli L, Bergaglio G, Garaifo G, Vitale N, Caputo M, Machirollati R et al: Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. Blood 127: 221-232, 2016.
12. George RE, Sanda T, Hanna M, Frothing S, Luehr W, Zhang J, Ahn Y, Zhou W, London WB, McGrady P et al: Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455: 975-978, 2008.
13. Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, Mori S, Ratzkin B and Yamamoto T: Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous oncogene. Oncogene 14: 439-449, 1997.
14. https://www.ncbi.nlm.nih.gov/nuccore/NM_004304?report=GenBank. Homo sapiens ALK receptor tyrosine kinase (ALK), transcript variant 1, mRNA.
15. https://www.ncbi.nlm.nih.gov/nuccore/NM_007439.2?report=GenBank. Mus musculus anaplastic lymphoma kinase (Alk), mRNA.
16. Forsea AM, Del Marmol V, de Vries E, Bailey EE and Geller AC: Melanoma incidence and mortality in Europe: New estimates, persistent disparities. Br J Dermatol 167: 1124-1130, 2012.
17. Svenman FC, Pillass D, Taylor A, Kaur M, Leiber R and Hansson J: Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe—a systematic review of the literature. Clin Epidemiol 8: 109-122, 2016.
18. Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR et al: Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res 3: 288-295, 2015.
19. Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlf ML, Richard J, Gershenwald JE, Kim KB et al: NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118: 4044-4043, 2012.
20. Arozarena I and Wellbrock C: Targeting invasive properties of melanoma cells. FEBS J 284: 2148-2162, 2017.
21. Thuil PJ, Akesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal I, Alm T, Asplund A, Björk L, Breckels LM et al: A subcellular map of the human proteome. Science 356: pii: eaal3321, 2017.
22. Morris SW, Kirstein MN, Valentine MB, Ditmer K, Shapiro DN, Alm T, Saha S, Shura S, Knox SJ et al: Impact of NRAS mutational analyses. PLoS One 10: e0121815, 2015.
23. Platz A, Egyhazi S, Ringleborg U and Hansson J: Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies of brain metastases from non-small cell lung cancer. Curr Oncol Rep 20: 54, 2018.
24. Breckels PM, Asplund A, Saha S, Shura S, Knox SJ, Morris SW, Ditmer K, Alm T, Saha S and Benveniste EN: Impact of NRAS mutational analyses. PLoS One 10: e0121815, 2015.
25. Shura S, Breckels PM, Asplund A, Saha S, Shura S, Knox SJ, Morris SW, Ditmer K, Alm T, Saha S and Benveniste EN: Impact of NRAS mutational analyses. PLoS One 10: e0121815, 2015.
26. Kim KB, Morris SW, Ditmer K, Alm T, Saha S, Shura S and Benveniste EN: Impact of NRAS mutational analyses. PLoS One 10: e0121815, 2015.